

Potential Role of iPSC Technology in Creating Exciting New Opportunities for Cardiovascular Research

Yuan Li*

National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Chaoyang, Beijing, China

Abstract

By providing structures to learn about the mechanisms of disease pathogenesis that should result in new therapies or reveal medication sensitivities, induced pluripotent stem cell (iPSC) technology is creating exciting new opportunities for cardiovascular research. The practical relevance of iPSC-derived cardiomyocytes in drug development and toxicity testing is explored in this study, with a focus on the advancements that have already been accomplished in this area. Additionally, it highlights the crucial steps that must be accomplished before this research may be widely applied in drug discovery and toxicological evaluations.

Keywords: iPSC, cardiovascular research, drug development, toxicity testing, disease pathogenesis

Introduction

Induced pluripotent stem cell (iPSC) technology has revolutionized the field of regenerative medicine and drug development. By reprogramming somatic cells, iPSCs can be differentiated into various cell types, including cardiomyocytes, which are essential for cardiovascular research. This technology offers a unique platform for studying disease mechanisms, testing drug efficacy, and identifying potential therapeutic targets. In this review, we explore the potential role of iPSC technology in creating exciting new opportunities for cardiovascular research. We discuss the practical relevance of iPSC-derived cardiomyocytes in drug development and toxicity testing, highlighting the advancements that have already been accomplished in this area. Additionally, we emphasize the crucial steps that must be accomplished before this research can be widely applied in drug discovery and toxicological evaluations. The use of iPSCs in cardiovascular research has gained significant momentum in recent years, with numerous studies demonstrating their utility in modeling disease states and testing potential treatments. For example, iPSC-derived cardiomyocytes have been used to study the effects of various drugs on cardiac function and to identify potential side effects. This approach has also been used to study the underlying mechanisms of various cardiovascular diseases, such as heart failure and arrhythmias. The ability to generate patient-specific iPSCs allows for personalized medicine, where treatments can be tailored to an individual's genetic profile. This is particularly important in the case of rare genetic disorders, where traditional animal models may not accurately represent the human condition. The use of iPSCs in cardiovascular research is also being leveraged to develop new therapies. For example, iPSC-derived cardiomyocytes are being used to study the effects of various drugs on cardiac function and to identify potential side effects. This approach has also been used to study the underlying mechanisms of various cardiovascular diseases, such as heart failure and arrhythmias. The ability to generate patient-specific iPSCs allows for personalized medicine, where treatments can be tailored to an individual's genetic profile. This is particularly important in the case of rare genetic disorders, where traditional animal models may not accurately represent the human condition. The use of iPSCs in cardiovascular research is also being leveraged to develop new therapies. For example, iPSC-derived cardiomyocytes are being used to study the effects of various drugs on cardiac function and to identify potential side effects. This approach has also been used to study the underlying mechanisms of various cardiovascular diseases, such as heart failure and arrhythmias. The ability to generate patient-specific iPSCs allows for personalized medicine, where treatments can be tailored to an individual's genetic profile. This is particularly important in the case of rare genetic disorders, where traditional animal models may not accurately represent the human condition.

*Corresponding author: Yuan Li, National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Chaoyang, Beijing, China, E-mail: yuanli@gamil.com

Received: 01-Nov-2022, Manuscript No. wjpt-23-87414; Editor assigned: 03-Nov-2022, PreQC No. wjpt-23-87414(PQ); Reviewed: 17-Nov-2022, QC No. wjpt-23-87414; Revised: 22-Nov-2022, Manuscript No. wjpt-23-87414(R); Published: 29-Nov-2022, DOI: 10.4172/wjpt.1000172

Citation: Li Y (2022) Potential Role of iPSC Technology in Creating Exciting New Opportunities for Cardiovascular Research. World J Pharmacol Toxicol 5: 172.

Copyright: © 2022 Li Y. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

... A... (A),... (),
(),...
A...
4-7.

...²⁺...
A...
A...

Abstract: Induced pluripotent stem (iPSC) technology has revolutionized the field of regenerative medicine and drug discovery. This technology allows for the generation of patient-specific pluripotent stem cells, which can be differentiated into various cell types, including cardiomyocytes. The use of iPSC technology in cardiovascular research offers several advantages, including the ability to model disease mechanisms, study drug toxicity, and develop personalized therapies. This review discusses the potential role of iPSC technology in creating exciting new opportunities for cardiovascular research, focusing on the generation of iPSC-derived cardiomyocytes and their application in disease modeling and drug discovery. The review also highlights the challenges and future perspectives of iPSC technology in cardiovascular research.

Keywords: iPSC, cardiovascular research, drug discovery, regenerative medicine, cardiomyocytes, disease modeling, personalized therapies.

Introduction: The field of regenerative medicine has seen significant advances in recent years, with the development of various stem cell-based therapies. Induced pluripotent stem (iPSC) technology has emerged as a powerful tool for generating patient-specific pluripotent stem cells, which can be differentiated into various cell types, including cardiomyocytes. The use of iPSC technology in cardiovascular research offers several advantages, including the ability to model disease mechanisms, study drug toxicity, and develop personalized therapies. This review discusses the potential role of iPSC technology in creating exciting new opportunities for cardiovascular research, focusing on the generation of iPSC-derived cardiomyocytes and their application in disease modeling and drug discovery. The review also highlights the challenges and future perspectives of iPSC technology in cardiovascular research.

1. Introduction

1.1. Overview of iPSC Technology

1.2. Applications of iPSC Technology in Cardiovascular Research

1.3. Challenges and Future Perspectives

2. Generation of iPSC-Derived Cardiomyocytes

2.1. Differentiation Protocols

2.2. Characterization of iPSC-Derived Cardiomyocytes

2.3. Applications of iPSC-Derived Cardiomyocytes in Disease Modeling and Drug Discovery

3. Disease Modeling and Drug Discovery

3.1. Modeling of Cardiovascular Diseases

3.2. Drug Toxicity Testing

3.3. Personalized Medicine

4. Challenges and Future Perspectives

4.1. Scalability and Cost

4.2. Safety and Efficacy

4.3. Regulatory Hurdles

5. Conclusion

References

- of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells. *Circ Cardiovasc Genet* 6:557-568.
8. Dubois NC, Craft AM, Sharma P, Elliott DM, Stanley EG, et al. (2011) SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. *Nat Biotechnol* 29:1011-1018.
 9. Egashira T, Yuasa S, Suzuki T, Aizawa Y, Yamakawa H, et al. (2012) Disease characterization using LQTS-specific induced pluripotent stem cells. *Cardiovasc Res* 95:419-429.
 10. Engler AJ, Carag-Krieger C, Johnson CP, Raab M, Tang HY, et al. (2008) Embryonic cardiomyocytes beat best on a matrix with heart-like elasticity: Scar-like rigidity inhibits beating. *J Cell Sci* 121:3794-3802.
 11. Fatima G, Xu K, Shao S, Papadopoulos M, Lehmann JJ, et al. (2011) In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. *Cell Physiol Biochem* 28:579-592.
 12. Gonzalez F, Boue S, Izpisua Belmonte JC (2011) Methods for making induced pluripotent stem cells: Reprogramming a la carte. *Nat Rev Genet* 12:231-242.
 13. Huber I, Itzhaki O, Caspi G, Arbel M, Tzukerman A, et al. (2007) Identification and selection of cardiomyocytes during human embryonic stem cell differentiation. *FASEB J*, 21:2551-2563.
 14. Itzhaki I, Maizels L, Huber I, Gepstein A, Arbel G, et al. (2012) Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human induced pluripotent stem cells. *J Am Coll Cardiol* 60:990-1000.
 15. Jia F, Wilson KD, Sun N, Gupta DM, Huang M, et al. (2010) A nonviral minicircle vector for deriving human iPS cells. *Nat Methods* 7:197-199.